In contrast, many other tumor types compensate for reduced endogenous synthesis by upregulating LDL receptor-mediated cholesterol uptake (Duan et al, 2022; Huang et al, 2020), but RMS cells demonstrate minimal metabolic redundancy, underscoring cholesterol biosynthesis as a non-redundant therapeutic target. The gene discussed is LDLR; the disease is neoplasm.